Folia Pharmacologica Japonica, 2011, Vol.138(5), pp.209-217
2011
Details
- Autor(en) / Beteiligte
- Titel
- Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer
- Ist Teil von
- Folia Pharmacologica Japonica, 2011, Vol.138(5), pp.209-217
- Ort / Verlag
- Japan: The Japanese Pharmacological Society
- Erscheinungsjahr
- 2011
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Sprache
- Japanisch
- Identifikatoren
- ISSN: 0015-5691eISSN: 1347-8397DOI: 10.1254/fpj.138.209Titel-ID: cdi_proquest_miscellaneous_904014095
- Format
- –
- Schlagworte
- Animals, Antineoplastic Agents - administration & dosage, Antineoplastic Agents - adverse effects, Antineoplastic Agents - pharmacokinetics, Antineoplastic Agents - pharmacology, Breast Neoplasms - drug therapy, Breast Neoplasms - pathology, Clinical Trials as Topic, Drug Administration Schedule, Drug Approval, Drug Discovery, Female, Furans - administration & dosage, Furans - adverse effects, Furans - pharmacokinetics, Furans - pharmacology, Humans, Infusions, Intravenous, Ketones - administration & dosage, Ketones - adverse effects, Ketones - pharmacokinetics, Ketones - pharmacology, Neoplasm Metastasis, Treatment Outcome, Tubulin Modulators - administration & dosage, Tubulin Modulators - adverse effects, Tubulin Modulators - pharmacokinetics, Tubulin Modulators - pharmacology